Rising Prevalence Of Cancer To Drive Market Growth Driver: A Major Catalyst in the Evolution of the Oncology Biomarkers Market in 2025

What industry-specific factors are fueling the growth of the oncology biomarkers market?
The increasing prevalence of cancer is projected to fuel the expansion of the oncology biomarker market. Cancer is a condition where certain cells in the body start growing without restraint and gradually invade the rest of the body. By studying the genes, proteins, and other elements in a person's body, oncology biomarkers can provide further information about the type of cancer. For example, the National Library of Medicine, a government institution in the U.S., predicted in January 2024 that there would be an estimate of 2,001,140 new cancer cases and 611,720 cancer-related fatalities in the United States in 2024. Moreover, the occurrence rates for cervical cancer among individuals aged between 30 and 44, and colorectal cancer in those aged under 55 have been observed to increase annually by 1% to 2% among young adults. Consequently, the escalating prevalence of cancer is expected to stimulate the growth of the oncology biomarker market.

Get Your Oncology Biomarkers Market Report Here:
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

What Is the projected market size and growth rate for the oncology biomarkers market?
There has been a significant expansion in the market size of oncology biomarkers in the past few years. The sector is expected to escalate from $15.3 billion in 2024 to $17.43 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.9%. This growth during the historic phase is primarily a result of areas like the growing acceptance in developing economies, initiatives for precision medicine, innovative diagnostics, supportive drug development, and a rise in cancer incidences.

The market size for oncology biomarkers is projected to experience accelerated expansion in the coming years, reaching $29.64 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 14.2%. This anticipated leap during the forecast period is largely fueled by the incorporation of next-generation sequencing (ngs), the development of biomarker informatics, the concentration on predictive pharmacogenomics, the swift advancement of exosome-based biomarkers, and the increasing adoption of spatial transcriptomics. Major emerging trends during this forecast period encompass the standardization and quality assurance, a shift towards functional biomarkers, the importance of biomarkers in clinical trials, the wide-ranging applications in immunotherapy, and the real-time surveillance of treatment reactions.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

What new trends are reshaping the oncology biomarkers market and its opportunities?
The deployment of groundbreaking and sophisticated technologies is a prevailing trend in the oncology biomarker sector. Leading firms in the oncology biomarkers industry are integrating fresh and innovative technologies for solidifying their dominance. For example, OncoDNA, a Belgium-based organization dedicated to precision medicine in oncology, rolled out OncoDEEP in 2022. This exceptional kit allows labs to conduct exhaustive biomarker examinations. It leverages Next-generation sequencing (NGS) technology and cloud-supported software applications to equip these labs with the capacity to carry out large-panel sequencing, extract the tumor's molecular description, scrutinize raw data, and execute extensive quality checks.

What major market segments define the scope and growth of the oncology biomarkers market?
The oncology biomarkers market covered in this report is segmented -

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers
2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types
4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers
2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)
3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12493

Which region dominates the oncology biomarkers market?
North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which key market leaders are driving the oncology biomarkers industry growth?
Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

What Is Covered In The Oncology Biomarkers Global Market Report?

• Market Size Forecast: Examine the oncology biomarkers market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the oncology biomarkers market for a structured understanding.
• Key Players Overview: Analyze major players in the oncology biomarkers market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the oncology biomarkers market.
• Segment Contributions: Evaluate how different segments drive overall growth in the oncology biomarkers market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the oncology biomarkers market.
• Industry Challenges: Identify potential risks and obstacles affecting the oncology biomarkers market.
• Competitive Landscape: Review strategic developments in the oncology biomarkers market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.